Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.

Date publication

janvier 2022

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier , Dr ROYER Bernard , Dr MANSI Laura , Pr HEYD Bruno , Dr PAQUETTE Brice , Dr DEMARCHI Martin , Dr LAKKIS Zaher

Tous les auteurs :
Paquette B, Kalbacher E, Mercier F, Lakkis Z, Doussot A, Turco C, Caputo E, Pili-Floury S, Royer B, Mansi L, Delroeux D, Demarchi M, Pivot X, Chauffert B, Clement E, Heyd B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34994906

Résumé

Ovarian cancer (OC) is the most lethal gynecological cancer. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy appears to increase survival, and normothermic intraperitoneal chemotherapy (IPC) could improve overall survival (OS). Furthermore, intraperitoneal epinephrine could decrease the toxicity of chemotherapy by decreasing the systemic absorption of chemotherapy. The goal of this study was to assess the effects of CRS and IPC with intraperitoneal epinephrine, as first-line therapy, on the survival of patients with serous epithelial OC (EOC) with peritoneal metastases.

Référence

Ann Surg Oncol. 2022 Jan 7;: